Abstract P2-10-15: Reproducibility of the interactions of race on outcomes and toxicities associated with treatment of HER2+ Breast Cancer across databases

Britney Fitzgerald, Justin Petucci, Vasant Honavar, Monali VasekarClinical 2025 · DOI

Abstract

Abstract Objective: Investigate the reproducibility of the interaction of race on outcomes and toxicities associated with HER2+BrCa treatment across multiple data sources. Background: HER2+ breast cancer (BrCa) is an aggressive subtype, accounting for 20-30% of all BrCa cases. Trastuzumab, a monoclonal anti-HER2 antibody, remains the cornerstone of treatment. Previously, we identified race as a factor associated with increased toxicities and poorer outcomes in HER2+BrCa treatment using the TrinetX Database. Further investigation into the outcomes and toxicities in minority groups is necessary, emphasizing the importance of utilizing databases for such research. Design/Methods: In this propensity score-matched cohort study we used the TriNetX Research Network to compare mortality of HER2+BrCa in non-Hispanic African American (NHAA) women to a corresponding non-Hispanic White cohort (NHW). Qualification into the two race based HER2+BrCa cohorts required the presence of a C50 ICD-10-CM diagnosis code and at least one proxy for HER2 positivity such as Trastuzumab (index event). Cohorts were matched for age, BMI, comorbidities, and lab values using 1:1 matching with a greedy nearest neighbor search. Toxicity outcomes were also compared between the cohorts. The associations of observed outcome frequencies in the two cohorts were tested for significance using the chi-square test. The odds ratios with 95% confidence intervals, are reported as an effect size and significance estimation. As a test of robustness of the results based on the TriNetX data, we compared the outcome of all time mortality after diagnosis across unmatched NHAA and NHW cohorts using the well-established SEER and NCDB patient-level databases. Results: Using SEER, 68,697 patients met the inclusion criteria for HER2+BrCa (57,554 NHW, 11,143 NHAA). The median age at the index event was 60-64 years for NHW and 55-59 years for NHAA. In the unmatched HER2+BrCa cohorts, the odds of death for NHAA were 1.32 times higher than for NHW, with a P-value of < 0.00001. Using NCDB, 352,553 patients met the inclusion criteria (305,219 NHW, 47,334 NHAA). In these cohorts, the odds of death for NHAA were 1.61 times higher than for NHW, also with a P-value of < 0.00001. Using TriNetX, the odds of death at 5 years after diagnosis for NHAA were 1.1379 times higher than for NHW in the unmatched HER2+BrCa cohorts, with a 95% confidence interval. TriNetX data also showed that NHAA women had significantly increased odds of neuropathy and cardiomyopathy at 1, 3, and 5-year intervals after the HER2+BrCa index date, compared to NHW women. Additionally, the odds of an emergency room visit (for any reason) were up to 79% higher in NHAA women compared to their NHW counterparts. There was a lack of detailed toxicity data points, such as neuropathy and cardiomyopathy, in the NCDB and SEER databases, preventing cross-comparison. Conclusion: We found increased odds of mortality for NHAA patients compared to NHW patients with HER2+BrCa undergoing Trastuzumab therapy across all three databases. Although toxicity data could not be directly compared across sources due to lack of granularity, the consistency of mortality findings highlights the reliability of our previous results from the TriNetX Database. In TriNetX, NHAA women with HER2+BrCa demonstrated higher odds of experiencing neuropathy, cardiomyopathy, and emergency room visits compared to their NHW counterparts. These results emphasize the importance of considering racial impact on HER2+BrCa outcomes and highlight the utility of real-world data sources like TriNetX for exploring BrCa outcomes and treatment toxicities. Our findings suggest the need for further research and targeted interventions to address disparities and improve treatment outcomes in diverse populations. Citation Format: Britney Fitzgerald, Justin Petucci, Vasant Honavar, Monali Vasekar. Reproducibility of the interactions of race on outcomes and toxicities associated with treatment of HER2+ Breast Cancer across databases [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P2-10-15.
BibTeX
@inproceedings{fitzgerald2025abstract,
  author = {Britney Fitzgerald and Justin Petucci and Vasant Honavar and Monali Vasekar},
  title = {{Abstract P2-10-15: Reproducibility of the interactions of race on outcomes and toxicities associated with treatment of HER2+ Breast Cancer across databases}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1557-3265.sabcs24-p2-10-15},
}

Loading related content...

Figure